These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35377447)

  • 1. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
    Price E; Bombardieri M; Kivitz A; Matzkies F; Gurtovaya O; Pechonkina A; Jiang W; Downie B; Mathur A; Mozaffarian A; Mozaffarian N; Gottenberg JE
    Rheumatology (Oxford); 2022 Nov; 61(12):4797-4808. PubMed ID: 35377447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA; Mariette X; Papas A; Grader-Beck T; Bootsma H; Ng WF; van Daele PLA; Finzel S; Noaiseh G; Elgueta S; Hermann J; McCoy SS; Akpek E; Bookman A; Sopala M; Montecchi-Palmer M; Luo WL; Scheurer C; Hueber W;
    Lancet; 2024 Aug; 404(10452):540-553. PubMed ID: 39096929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
    Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
    Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
    Werth VP; Fleischmann R; Robern M; Touma Z; Tiamiyu I; Gurtovaya O; Pechonkina A; Mozaffarian A; Downie B; Matzkies F; Wallace D
    Rheumatology (Oxford); 2022 May; 61(6):2413-2423. PubMed ID: 34498056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
    Xu D; Fang J; Zhang S; Huang C; Huang C; Qin L; Li X; Chen M; Liu X; Liu Y; Li Z; Hu J; Bao C; Wei W; Tian J; Duan X; Zeng X
    Rheumatology (Oxford); 2024 Mar; 63(3):698-705. PubMed ID: 37399108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
    Baker M; Chaichian Y; Genovese M; Derebail V; Rao P; Chatham W; Bubb M; Lim S; Hajian H; Gurtovaya O; Patel U; Tumlin J
    RMD Open; 2020 Dec; 6(3):. PubMed ID: 33380521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.
    Bentley D; Fisher BA; Barone F; Kolb FA; Attley G
    Rheumatology (Oxford); 2023 Nov; 62(11):3644-3653. PubMed ID: 36864622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.